ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Position Raised by New York State Teachers Retirement System

New York State Teachers Retirement System increased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 24.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 113,090 shares of the biotechnology company's stock after purchasing an additional 21,976 shares during the quarter. New York State Teachers Retirement System's holdings in ADMA Biologics were worth $1,939,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after buying an additional 967 shares during the last quarter. State of Alaska Department of Revenue grew its position in shares of ADMA Biologics by 1.0% during the 4th quarter. State of Alaska Department of Revenue now owns 134,346 shares of the biotechnology company's stock valued at $2,304,000 after buying an additional 1,337 shares during the last quarter. Hollencrest Capital Management bought a new stake in shares of ADMA Biologics in the 3rd quarter worth approximately $30,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of ADMA Biologics by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock worth $163,000 after purchasing an additional 1,509 shares during the last quarter. Finally, Larson Financial Group LLC bought a new stake in shares of ADMA Biologics in the 3rd quarter worth approximately $31,000. 75.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ADMA shares. HC Wainwright raised their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Raymond James upped their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th.

ADMA Biologics Price Performance

NASDAQ:ADMA traded up $0.04 during mid-day trading on Monday, reaching $15.88. 635,091 shares of the stock were exchanged, compared to its average volume of 2,240,263. ADMA Biologics, Inc. has a 1-year low of $5.08 and a 1-year high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $3.75 billion, a PE ratio of 56.71 and a beta of 0.75. The business has a fifty day moving average price of $16.97 and a 200 day moving average price of $18.00.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.